Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
Author Department
Medicine
Document Type
Article, Peer-reviewed
Publication Date
11-1-2008
Recommended Citation
Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, Barkhaus PE, Bosch P, Boylan K, David WS, Feldman E, Glass J, Gutmann L, Katz J, King W, Luciano CA, McCluskey LF, Nash S, Newman DS, Pascuzzi RM, Pioro E, Sams LJ, Scelsa S, Simpson EP, Subramony SH, Tiryaki E, Thornton CA. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial Neurology 2008 Nov;71(22):1770-5.
COinS